Exozymes Inc. (EXOZ) stock
EXOZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.83−0.17 (-4.25%)
Close on Nov 13, 2026Market cap $35.55MP/E –Yield –
Exozymes EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Exozymes's EPS for the twelve months ending Sep 30, 2026 was -$1.17. For fiscal 2025 it was -$1.09.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.09 | – |
| FY2024 | Dec 31, 2024 | -$0.89 | – |
| FY2023 | Dec 31, 2023 | -$0.33 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.24 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.33 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.28 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.32 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.27 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.28 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.22 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.24 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.27 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.22 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.16 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.18 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.08 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?